Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02201212
Title Everolimus for Cancer With TSC1 or TSC2 Mutation
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

Advanced Solid Tumor

Therapies

Everolimus

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Dana Farber Cancer Institute Boston Massachusetts 02115 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field